Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Teva R&D Initiative |
---|---|
Information provided by: | Teva R&D Initiative |
ClinicalTrials.gov Identifier: | NCT00287157 |
Nightly administration of a unique, sublingual (under the tongue) formulation of tizanidine, a known anti-spasticity medication, has been shown in a previous study to improve sleep and next-day functioning in CP (cerebral palsy) patients. It is hypothesized that this improvement in sleep efficiency (i.e.,fewer wake episodes, longer time asleep, etc.) with resulting improvement in quality-of-life (i.e.,improvements in next-day functioning, cognition and movement) may also be seen in a similar patient population, i.e., children with traumatic brain injury (TBI).
Condition | Intervention | Phase |
---|---|---|
Traumatic Brain Injury |
Drug: Sublingual Tizanidine HCl |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Crossover Assignment, Safety/Efficacy Study |
Official Title: | A Double-Blind, Randomized, Two-Way Crossover, Comparative Study to Evaluate the Clinical Efficacy and Safety of Novel Sublingual Tizanidine HCl Versus Placebo in Children With Chronic Traumatic Brain Injury |
Enrollment: | 5 |
Study Start Date: | December 2006 |
Study Completion Date: | May 2007 |
Sublingual tizanidine, a novel test formulation of the known effective antispasticity agent, has been shown to have a unique pharmacokinetic profile [(i.e., nearly twice the bioavailability/AUC), but with little or no increase in peak plasma levels (Cmax), as compared to oral tizanidine (Zanaflex)].
When administered nightly to CP (Cerebral Palsy) patients to more effectively reduce the muscle spasms that disrupt sleep, it was shown to improve sleep efficiency, decrease sleep fragmentation and improve the sleep cycle. This improvement in night-time sleep was translated into a potential improvement in next-day functioning (improvement in next-day measures of spasticity and movement).
It is hypothesized that a similar type of improvement in sleep with consequent positive impact on next day improvement in spasticity, cognition and function, may also be manifest in a similar patient population, children with traumatic brain injury.
Ages Eligible for Study: | 8 Years to 18 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Israel | |
Alyn Hospital Pediatric and Adolescent Rehabilitation Center | |
Jerusalem, Israel, 01090 |
Principal Investigator: | Ido Yatsiv, MD | Hadassah Medical Center, Ein Kerem, Jerusalem |
Study ID Numbers: | Protocol C2/5/TZ-TBI-01 |
Study First Received: | February 2, 2006 |
Last Updated: | January 20, 2009 |
ClinicalTrials.gov Identifier: | NCT00287157 History of Changes |
Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Traumatic Brain Injury Actigraphy Spasticity, Cognition and Functioning |
Craniocerebral Trauma Neurotransmitter Agents Adrenergic alpha-Agonists Adrenergic Agents Wounds and Injuries Central Nervous System Diseases Disorders of Environmental Origin Trauma, Nervous System Brain Diseases |
Adrenergic Agonists Muscle Spasticity Muscle Relaxants, Central Peripheral Nervous System Agents Analgesics Tizanidine Brain Injuries Anticonvulsants |
Craniocerebral Trauma Parasympatholytics Neurotransmitter Agents Adrenergic Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Disorders of Environmental Origin Neuromuscular Agents Brain Diseases Adrenergic Agonists Sensory System Agents Therapeutic Uses Muscle Relaxants, Central |
Tizanidine Analgesics Brain Injuries Adrenergic alpha-Agonists Nervous System Diseases Wounds and Injuries Central Nervous System Diseases Trauma, Nervous System Pharmacologic Actions Autonomic Agents Peripheral Nervous System Agents Central Nervous System Agents Anticonvulsants |